Impower133 sclc
WitrynaThe IMpower133 regimen, composed of atezolizumab/etoposide (VP-16)/carboplatin (CBDCA), is the standard first-line treatment for extensive-stage small cell lung … Witryna11 kwi 2024 · 在我们的系统综述和nmas中，评估了es-sclc使用icis的生存获益和安全性，并探讨了最适合患者的治疗方法。 我们的研究结果显示，相比于其他icis， 斯鲁利单抗+化疗最有可能为es-sclc总人群带来更好的pfs和os生存获益，阿得贝利单抗+化疗带来更好os获益的可能性次之；
Impower133 sclc
Did you know?
WitrynaSafety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial … Witryna31 sty 2024 · The latest data from the IMpower 133 trial shows that maintenance therapy with atezolizumab (Tecentriq) plus carboplatin and etoposide (CP/ET) improves overall survival (OS) and progression-free...
Witryna1 dzień temu · IMpower133、CASPIAN两项III期研究先后取得阳性结果[16,17]，并获批ES-SCLC适应症，开启了小细胞肺癌免疫治疗新纪元，中国自主研发的阿得贝利单抗CAPSTONE-1研究，进一步验证了PD-L1抑制剂在ES-SCLC中的标准治疗地位，研究结果荣登The Lancet Oncology，随着适应症的获批 ... Witryna18 cze 2024 · IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line carboplatin and etoposide ± atezolizumab ESMO Virtual Plenary Session date: 17-18 June 2024 Access to this content is restricted Please login with your ESMO Account Abstract
WitrynaResults are consistent with the primary analysis of the IMpower133 trial. The addition of atezolizumab to carboplatin and etoposide was effective and well-tolerated in … Witryna• The recently published IMpower133 (NCT02763579) study demonstrated that the addition of atezolizumab, a humanised monoclonal anti–PD-L1 antibody, to …
Witryna26 wrz 2024 · In the IMpower133 double-blind, placebo-controlled, phase 3 trial, treatment-naïve patients with ES-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were randomized to receive EP (with carboplatin) with either atezolizumab or placebo for four 21-day cycles (induction phase) followed …
Witryna29 cze 2024 · In March 2024, the FDA approved the use of the anti-programmed death ligand 1 (PD-L1) antibody atezolizumab, as a first-line treatment option in combination with platinum-etoposide (PE) for patients with extensive stage small cell lung cancer (ED SCLC) based upon the results of the IMpower133 trial. More recently, the FDA … rct-6000-wptuWitryna22 sty 2024 · SCLC is known for rapid, aggressive growth and resistance to treatment, which leads to poor outcomes. ... Byers' team also analyzed data from 276 SCLC patients enrolled in the Phase III IMpower133 ... sims townshipWitrynaIMpower133, a global Ph1/3, double-blind, randomized, placebo (PBO)-controlled trial evaluated efficacy and safety of adding atezolizumab (atezo; anti–PD-L1) or PBO to 1L tx (NCT02763579). Methods Patient (pts) without prior tx for ES-SCLC were enrolled. PD-L1 testing was not required. rct6773w42bf cameraWitryna25 maj 2024 · Small cell lung cancer (SCLC) is still a lethal disease. Three phase III randomized clinical trials (IMpower133, CASPIAN, and KEYNOTE-604) have highlighted the survival gain of adding immune ... rct600wWitrynaIMpower133及CASPIAN研究在ES-SCLC患者一线治疗中均取得了总生存期（overall survival, OS）的突破性进展，由此FDA批准PD-L1单克隆抗体Atezolizumab（阿特珠单抗）[8]及Durvalumab（德瓦鲁单抗）[9]与卡铂和依托泊苷联合用于ES-SCLC患者的一线治疗。 但是，在2024年美国临床肿瘤 ... sims township michiganWitryna3 lut 2024 · Updated data regarding overall survival (OS) from the IMpower133 trial (NCT02763579) indicate that maintenance therapy with atezolizumab (Tecentriq) plus carboplatin and etoposide (CP/ET) is superior to placebo and CP/ET for the treatment of extensive-stage small cell lung cancer (ES-SCLC). 1 rct6272w23 chargerWitryna11 lut 2024 · Gay et al. aligned IMpower133 patient data with their four subgroups and re-analyzed patient survival. Although this trial was not designed for this subset … rct6103w46 replacement battery